These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24508555)

  • 1. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.
    Shah DK; Balthasar JP
    Int J Pharm; 2014 Apr; 465(1-2):228-38. PubMed ID: 24508555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan.
    Shah DK; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):55-69. PubMed ID: 24368689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
    Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
    Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice.
    Chen J; Lu Q; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2007 Dec; 34(6):829-47. PubMed ID: 17885736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.
    Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic model for topotecan in mice.
    Shah DK; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):121-42. PubMed ID: 21104004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.
    Shah DK; Shin BS; Veith J; Tóth K; Bernacki RJ; Balthasar JP
    J Pharmacol Exp Ther; 2009 May; 329(2):580-91. PubMed ID: 19233938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the Influence of Protein-Losing Enteropathy on Monoclonal Antibody Pharmacokinetics in Mice.
    Yang Y; Li TR; Balthasar JP
    AAPS J; 2017 Nov; 19(6):1791-1803. PubMed ID: 28849396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of near infrared fluorescent labeling of monoclonal antibodies as a tool for tissue distribution.
    Conner KP; Rock BM; Kwon GK; Balthasar JP; Abuqayyas L; Wienkers LC; Rock DA
    Drug Metab Dispos; 2014 Nov; 42(11):1906-13. PubMed ID: 25209366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.
    Abuqayyas L; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.
    Roberts JK; Birg AV; Lin T; Daryani VM; Panetta JC; Broniscer A; Robinson GW; Gajjar AJ; Stewart CF
    Drug Metab Dispos; 2016 Jul; 44(7):1116-22. PubMed ID: 27052877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy.
    Engler FA; Zheng B; Balthasar JP
    Pharm Res; 2014 May; 31(5):1185-93. PubMed ID: 24203494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.
    Bączek T; Konieczna L; Belka M; Maciejka-Kapuścińska L; Wiśniewski J; Niedźwiecki M; Balcerska A; Adamkiewicz-Drożyńska E; Wachowiak J
    J Pharm Biomed Anal; 2012 Nov; 70():330-6. PubMed ID: 22658903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
    Varkhede N; Forrest ML
    J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Therapeutic Efficacy of Topotecan Against A549 Lung Cancer Cells with Folate-targeted Topotecan Liposomes.
    Zhang J; Shi W; Xue G; Ma Q; Cui H; Zhang L
    Curr Drug Metab; 2020; 21(11):902-909. PubMed ID: 32851958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
    Hu S; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Two-Pore Physiologically Based Pharmacokinetic Model to Predict Subcutaneously Administered Different-Size Antibody/Antibody Fragments.
    Li Z; Yu X; Li Y; Verma A; Chang HP; Shah DK
    AAPS J; 2021 May; 23(3):62. PubMed ID: 33942169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.